Page last updated: 2024-12-10
cetoleic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
cetoleic acid: RN given refers to cpd with specified locant & without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
cetoleic acid : A docosenoic acid having a cis-double bond at position 11. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5282771 |
| CHEMBL ID | 3103072 |
| CHEBI ID | 32428 |
| SCHEMBL ID | 198161 |
| MeSH ID | M0064052 |
Synonyms (38)
| Synonym |
|---|
| cis-docos-11-enoic acid |
| docos-11c-enoic acid |
| cis-delta(11)-docosenoic acid |
| docos-11c-ensaeure |
| (z)-docos-11-enoic acid |
| cetoleic acid |
| cis-11-docosenoic acid |
| c22:1, n-11 cis |
| (z)-11-docosenoic acid |
| (11z)-docos-11-enoic acid |
| 1002-96-6 |
| CHEBI:32428 , |
| cetoleinsaeure |
| 22:1, n-11 cis |
| cis-cetoleic acid |
| LMFA01030088 |
| 11z-docosenoic acid |
| unii-62ezi2c5se |
| 11-docosenoic acid, (z)- |
| 62ezi2c5se , |
| SCHEMBL198161 |
| CHEMBL3103072 |
| cetolic acid |
| 22:1(n-11) |
| j12.483d , |
| (11z)-11-docosenoic acid |
| 11-docosenoic acid, cis- |
| KJDZDTDNIULJBE-QXMHVHEDSA-N |
| cis-cetoleate |
| 11z-docosenoate |
| cis-cetoleic acid (cis-22:1n-11) |
| DTXSID00920491 |
| Q27114930 |
| 11-docosenoic acid, (11z)- |
| PD150669 |
| fatty acid cis 22:1 n-11 |
| c22:1.n-11 cis |
| fatty acid 22:1 n-11 cis |
Research Excerpts
Overview
Cetoleic acid (22:1n-11) has proven to be an important fatty acid (FA) when using adipose tissue FA composition to study diet in marine mammals and seabirds.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cetoleic acid (22:1n-11) is a good indicator of diet in marine predators and has proven to be an important fatty acid (FA) when using adipose tissue FA composition to study diet in marine mammals and seabirds. " | ( Metabolism of dietary cetoleic acid (22:1n-11) in mink (Mustela vison) and gray seals (Halichoerus grypus) studied using radiolabeled fatty acids. Cooper, MH; Iverson, SJ; Rouvinen-Watt, K, ) | 1.89 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| Daphnia tenebrosa metabolite | A Daphnia metabolite produced by the species Daphnia tenebrosa. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (1)
| Class | Description |
|---|---|
| docosenoic acid | A C22, monounsaturated fatty acid carrying a C=C double bond at any position. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1063391 | Induction of dendrite extension in rat cortical neurons assessed as inhibition of amyloid beta (25 to 35)-induced neuronal degeneration at 1 uM after 4 days by fluorescence microscopic analysis | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Synthesis of long-chain fatty acid derivatives as a novel anti-Alzheimer's agent. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 30.23
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.23) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (12.50%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||